These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 37660335)

  • 1. Systemic Treatment for Cholangiocarcinoma.
    Sookprasert A; Wirasorn K; Chindaprasirt J; Watcharenwong P; Sanlung T; Putraveephong S
    Recent Results Cancer Res; 2023; 219():223-244. PubMed ID: 37660335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
    Lodl E; Ramnaraign B; Sahin I; Wheeler S
    J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
    Merath K; Tiwari A; Parikh AA; Pawlik TM
    Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current Studies and Evidence in Cholangiocarcinoma].
    Zimpel C; Mitzlaff K; Jasper NA; Marquardt JU
    Zentralbl Chir; 2022 Aug; 147(4):389-397. PubMed ID: 35863357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
    Uson Junior PLS; Bearss J; Babiker HM; Borad MJ
    Expert Opin Investig Drugs; 2023 Jan; 32(1):69-75. PubMed ID: 36714945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
    Du J; Lv X; Zhang Z; Huang Z; Zhang E
    Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
    Ang C
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
    Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
    Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
    [No Abstract]   [Full Text] [Related]  

  • 16. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
    Becht R; Wasilewicz MP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
    Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
    Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
    Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.